Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81417-exome-sequence-reevaluation
    Ask Trek AI about this page

    CPT 81417: Exome Reanalysis for New Clinical Information

    Commercial payers pay $332 on average nationally for this procedure.

    CPT code 81417 describes a laboratory reanalysis of an existing patient exome sequencing result when new clinical information or previously unavailable evidence emerges; this service is a targeted reinterpretation of prior exome data to reassess variant classification and clinical significance. The service type is exome reanalysis / reinterpretation and the typical site of service is clinical molecular diagnostics laboratory performing genomic data review and reporting.

    For related coverage guidance, see recent payer policy updates: Oral Cancer Screening and Testing, RTM Testing for Alpha-1 Antitrypsin Deficiency, Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policy.

    Customize your policy alerts

    Sign up for cpt 81417 policy alerts

    Get alerted when payer policies referencing 81417 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial reimbursement for CPT 81417 clusters around BUCA’s average commercial rate of $331.70, with individual payer medians and means showing meaningful variation. Blue Cross Blue Shield (BCBS) and Cigna exhibit higher central tendencies (BCBS median $324.40, Cigna median $286.70) while Aetna and UnitedHealth Group trend lower in median and mean levels; this places BUCA’s average near the upper middle of the payer mix.

    Dispersion measured by the interquartile spread (P75 minus P25) highlights differences in consistency: Blue Cross Blue Shield has the widest IQR at $107.30 (P75 $381.90 minus P25 $274.60), followed by Cigna at $253.40 (P75 $417.90 minus P25 $164.50) and BUCA at $140.60 (P75 $361.10 minus P25 $220.50). Aetna is the tightest at $116.40 (P75 $262.40 minus P25 $146.00), with UnitedHealth Group showing moderate spread of $176.00 (P75 $320.00 minus P25 $134.40).

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 58-year-old patient with a prior clinical exome sequencing report for evaluation of a suspected hereditary cancer predisposition (initial test performed two years earlier) presents after new clinical developments: progression of an indeterminate lung lesion and new family history revealing a first-degree relative with early-onset colon cancer. The laboratory receives a written request from the ordering oncologist to perform a reanalysis of the previously generated exome sequence data (not a repeat sequencing run) to assess whether newly published variant classifications, updated population frequency data, or additional phenotype information change the interpretation of previously reported variants.

    The clinical workflow: the laboratory confirms access to the archived raw sequence and variant call files for the patient, documents the updated clinical information and family history in the lab information system, and performs bioinformatic reannotation using current databases (ClinVar, gnomAD, locus-specific databases) and updated interpretation guidelines (ACMG/AMP). The lab analyst evaluates any newly reported or reclassified variants, prepares an amended/updated report describing variant reclassification, clinical significance, and potential implications for targeted therapy or surveillance, and communicates results to the ordering oncologist. Billing uses 81417 for the reanalysis service, with appropriate modifier selection and supporting notes in the report indicating the new information that prompted reanalysis.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207ZP0102X
    207ZP0007X
    207L00000X
    2278P3800X
    310400000X
    207UN0903X
    293D00000X
    261QA1903X

    Related ICD-10-CM Codes

    28 rows

    ICD-10-CM CodeDescription
    C18.9Malignant neoplasm of colon, unspecified
    C25.9Malignant neoplasm of pancreas, unspecified
    C34.90Malignant neoplasm of unspecified part of unspecified bronchus or lung
    C50.919Malignant neoplasm of unspecified site of unspecified female breast
    C61Malignant neoplasm of prostate
    C79.9Secondary malignant neoplasm of unspecified site
    C90.00Multiple myeloma not having achieved remission
    D82.1Di George's syndrome
    D82.9Immunodeficiency associated with major defect, unspecified
    E78.5Hyperlipidemia, unspecified

    Showing 1–10 of 28

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Carrier Testing Panels for Genetic Diseases (for Kentucky Only)UnitedHealthcare2026-10-01
    Genetic Testing for Neurological Disorders (for Kansas Only)UnitedHealthcare2026-10-01
    Genetic and Molecular TestingProvidence Health Plan2026-10-01
    Cell-Free Fetal DNA Testing (for Idaho Only)UnitedHealthcare2026-10-01
    Next Generation Sequencing for Minimal Residual Disease DetectionProvidence Health Plan2026-10-01
    Pharmacogenetic Panel Testing (for Kansas Only)UnitedHealthcare2026-10-01
    Non-Covered Genetic Panel TestsProvidence Health Plan2026-10-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    CPT-81420-NIPS-FETAL-ANEUPLOIDY-SEQUENCING-PANEL

    CPT 81420: Cell-Free Fetal DNA Panel for Chromosomes 13, 18, 21

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    81416
    Exome sequence analysis in a relative to create a reference exome for comparison
    Performed when a family member's exome is sequenced to assist interpretation of variants in the proband; may precede or accompany 81417 reanalysis if a new reference exome becomes available.
    81415Exome sequence analysis to look for genetic changes explaining an unexplained disorder or syndromeRepresents initial diagnostic exome sequencing; 81417 is used for subsequent reanalysis of that prior exome when new information arises.
    81418Pharmacogenomic panel (≥6 genes including CYP2C19 and CYP2D6)Distinct targeted pharmacogenomic testing that may be ordered separately to guide therapy; not a substitute for 81417 but may be ordered in parallel for therapeutic decision-making.